Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
NCT04093505 · University Hospital Heidelberg · PHASE3 · terminated · last registry update 2022-07-01 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study turned out no longer feasible. End of Recruitment: 25.5.2022” | Open Targets' class: invalid reason, study design | Registry record, University Hospital Heidelberg |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SMO in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-05-24Results posted on the registry: M.D. Anderson Cancer Center, Anti-OX40 Agonist Monoclonal Antibody PF-04518600 + Avelumab (NCT03390296)
- 2022-06-09Also stopped (withdrawn): City of Hope Medical Center, Bosutinib Monohydrate + Decitabine (NCT04655391)
- 2022-03-18Results posted on the registry: Pfizer, PF-04449913 + PF-04449913 (NCT02038777)
- 2022-01-25Results posted on the registry: University of Colorado, Denver, PF-04449913 (NCT01841333)
- 2021-10-15Results posted on the registry: Yale University, Glasdegib + Decitabine (NCT04051996)
- 2021-10-15Also stopped (terminated): Yale University, Glasdegib + Decitabine (NCT04051996)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision